Skip to main content
. 2025 Jul 21;8(7):e71013. doi: 10.1002/hsr2.71013

Table 1.

Characteristics of study participants at baseline.

Variable Total (n = 18,146) No statin use (n = 10,259) Statin use (n = 7887) p
Age, year 63.4 ± 16.0 59.0 ± 17.6 69.1 ± 11.4 < 0.001
Sex, female, n (%) 7217 (39.8) 4468 (43.6) 2749 (34.9) < 0.001
BMI, kg/m2 29.1 ± 6.6 28.7 ± 6.7 29.6 ± 6.4 < 0.001
Insurance type, n (%) < 0.001
Medicaid 1377 (7.6) 1050 (10.2) 327 (4.1)
Medicare 7920 (43.6) 3961 (38.6) 3959 (50.2)
Other 8849 (48.8) 5248 (51.2) 3601 (45.7)
Marital status, n (%) < 0.001
Unmarried 7801 (43.0) 4879 (47.6) 2922 (37)
Married 8277 (45.6) 4014 (39.1) 4263 (54.1)
Unknown 2068 (11.4) 1366 (13.3) 702 (8.9)
Ethnicity, n (%) < 0.001
Caucasian 11,714 (64.6) 6254 (61) 5460 (69.2)
Other 6432 (35.4) 4005 (39) 2427 (30.8)
CRRT, n (%) 1354 (7.5) 913 (8.9) 441 (5.6) < 0.001
Vasoactive drugs, n (%) 11,792 (65.0) 6003 (58.5) 5789 (73.4) < 0.001
Heart rate (bpm) 85.7 ± 15.3 88.1 ± 16.6 82.6 ± 12.9 < 0.001
MAP (mmHg) 77.0 ± 9.6 77.9 ± 10.2 75.8 ± 8.5 < 0.001
Respiration rate (bpm) 19.1 ± 3.8 19.5 ± 4.1 18.5 ± 3.3 < 0.001
Temperature (°C) 36.9 ± 0.6 37.0 ± 0.7 36.8 ± 0.5 < 0.001
WBC count (×109) 13.3 ± 6.8 13.2 ± 7.4 13.5 ± 6.0 0.012
Hb (g/L) 10.6 ± 2.0 10.7 ± 2.1 10.5 ± 1.8 < 0.001
Plt (×109) 197.5 ± 102.6 203.8 ± 112.6 189.2 ± 87.3 < 0.001
Glucose (mmol/L) 143.2 ± 44.6 142.9 ± 47.6 143.5 ± 40.4 0.405
Sodium (mmol/L) 138.7 ± 4.5 138.9 ± 5.0 138.5 ± 3.8 < 0.001
Potassium (mmol/L) 4.3 ± 0.6 4.2 ± 0.6 4.4 ± 0.6 < 0.001
BUN (mg/dL) 18.5 (13.0, 29.5) 19.0 (12.5, 31.0) 18.5 (14.0, 27.5) 0.13
Scr (mg/dL) 1.0 (0.8, 1.5) 1.0 (0.7, 1.5) 1.0 (0.8, 1.4) 0.02
PH 7.4 ± 0.1 7.4 ± 0.1 7.4 ± 0.1 < 0.001
PCO2 (mmHg) 42.1 ± 9.1 42.3 ± 10.0 41.9 ± 7.7 0.01
PaO2/FiO2 281.3 ± 119.4 284.5 ± 125.4 277.0 ± 111.1 < 0.001
Lactate 2.4 ± 1.7 2.6 ± 1.9 2.2 ± 1.4 < 0.001
SAPS II 41.7 ± 14.6 41.3 ± 15.8 42.2 ± 12.7 < 0.001
SOFA score 6.4 ± 3.5 6.6 ± 3.9 6.3 ± 3.0 < 0.001
Charlson comorbidity index 5.6 ± 2.9 5.1 ± 3.1 6.1 ± 2.4 < 0.001
Sepsis, n (%) 12,705 (70.0) 7593 (74) 5112 (64.8) < 0.001
MI, n (%) 3520 (19.4) 949 (9.3) 2571 (32.6) < 0.001
CHF, n (%) 5040 (27.8) 2244 (21.9) 2796 (35.5) < 0.001
CBVD, n (%) 3013 (16.6) 1642 (16) 1371 (17.4) 0.013
CPD, n (%) 4644 (25.6) 2465 (24) 2179 (27.6) < 0.001
Rheumatic disease, n (%) 573 (3.2) 323 (3.1) 250 (3.2) 0.935
Diabetes without complication, n (%) 4301 (23.7) 1869 (18.2) 2432 (30.8) < 0.001
Diabetes with complications, n (%) 1709 (9.4) 704 (6.9) 1005 (12.7) < 0.001
Renal disease, n (%) 3477 (19.2) 1629 (15.9) 1848 (23.4) < 0.001
Malignant cancer, n (%) 1972 (10.9) 1420 (13.8) 552 (7) < 0.001
Severe liver disease, n (%) 1148 (6.3) 1044 (10.2) 104 (1.3) < 0.001
Analgesia, h, median (IQR) 62.0 (27.0, 147.0) 68.0 (26.0, 171.5) 56.0 (28.0, 120.0) < 0.001
Sedation, h, median (IQR) 62.0 (27.2, 161.0) 78.0 (33.0, 196.0) 48.0 (23.0, 116.0) < 0.001
Delirium, n (%) 1381 (7.6) 757 (7.4) 624 (7.9) 0.18
Ventilation, h, median (IQR) 22.0 (10.0, 64.0) 29.0 (13.0, 81.0) 16.0 (8.0, 42.0) < 0.001
ICU stay, d 3.7 (2.0, 7.7) 4.1 (2.2, 8.8) 3.2 (1.7, 6.2) < 0.001
Hospital stay, d 9.2 (5.7, 15.9) 9.8 (5.6, 17.9) 8.8 (5.9, 13.9) < 0.001
30‐day mortality, n (%) 3051 (16.8) 2275 (22.2) 776 (9.8) < 0.001
90‐day mortality, n (%) 3264 (18.0) 2437 (23.8) 827 (10.5) < 0.001

Note: For each variable, mean ± standard deviation, median (interquartile range), or number (percent) was reported (as appropriate).

Abbreviations: BMI, body mass index; BUN, blood urea nitrogen; CBVD, cerebrovascular disease; CHF, congestive heart failure; CPD, chronic pulmonary disease; CRRT, continuous renal replacement therapy; d, days; h, hours; Hb, hemoglobin; MAP, mean arterial pressure; MI, myocardial infarct; PLT, platelets; SAPS, simplified acute physiology Score; Scr, serum creatinine; SOFA, sequential organ failure assessment; WBC, white blood cell.